Neoadjuvant Nivolumab Alone or in Combination with Relatlimab or Ipilimumab in Resectable Head and Neck Squamous Cell Carcinoma (HNSCC).
JOURNAL OF CLINICAL ONCOLOGY（2023）
Key words
Combination Therapies
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined